Lipitor atorvastatin: Post-marketing study data

Data from a subgroup analysis of 1,859 patients with coronary heart disease (CHD), chronic kidney disease (CKD) and metabolic syndrome in the 5-year, international TNT trial in 10,001 patients showed that 80 mg Lipitor reduced the risk of major cardiovascular events by 35% vs. 10 mg Lipitor (p=0.003). An additional subgroup analysis of 954 patients with CHD, CKD and obesity from the TNT trial showed that 80 mg Lipitor reduced the risk by 33% compared with 10 mg Lipitor (p=0.03). Data were presented at the American College of Cardiology meeting in Atlanta. ...